KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Tax Provisions (2016 - 2025)

Historic Tax Provisions for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $619000.0.

  • CRISPR Therapeutics AG's Tax Provisions fell 3122.22% to $619000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 1875.0%. This contributed to the annual value of $4.1 million for FY2024, which is 2291.67% up from last year.
  • As of Q3 2025, CRISPR Therapeutics AG's Tax Provisions stood at $619000.0, which was down 3122.22% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Tax Provisions peaked at $6.1 million during Q2 2022, and registered a low of -$8.5 million during Q4 2022.
  • In the last 5 years, CRISPR Therapeutics AG's Tax Provisions had a median value of $900000.0 in 2024 and averaged $678473.7.
  • The largest annual percentage gain for CRISPR Therapeutics AG's Tax Provisions in the last 5 years was 93575.0% (2021), contrasted with its biggest fall of 107958.12% (2021).
  • CRISPR Therapeutics AG's Tax Provisions (Quarter) stood at -$2.3 million in 2021, then crashed by 277.94% to -$8.5 million in 2022, then surged by 107.19% to $612000.0 in 2023, then surged by 91.34% to $1.2 million in 2024, then crashed by 47.14% to $619000.0 in 2025.
  • Its last three reported values are $619000.0 in Q3 2025, $1.3 million for Q2 2025, and $1.1 million during Q1 2025.